| Project/Area Number |
20591721
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Cerebral neurosurgery
|
|---|
| Research Institution | Keio University |
|---|
Principal Investigator |
SASAKI Hikaru Keio University, 医学部, 講師 (70245512)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HIROSE Yuichi 藤田保健衛生大学, 医学部, 教授 (60218849)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
YOSHIDA Kazunari 慶應義塾大学, 医学部, 教授 (70166940)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2010: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2009: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2008: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 脳腫瘍学 / 遺伝子 / 癌 / 神経膠腫 / グリオーマ / 1p / 19q / neoadjuvant / 個別化治療 / 脳・神経 / glioma / lp |
|---|
| Research Abstract |
We have prospectively conducted, on a daily basis, molecular studies on all resected gliomas including CGH and methylation-specific PCR of the MGMT gene. As a result, we found that adult supratentorial grade 2-3 gliomas are divided into clinically relevant subgroups by genetic profile (Hirose, 2011), and that single-copy gain of chromosome 1q is frequent in pediatric gliomas, and is associated with poor clinical outcome (Miwa, 2011). Moreover, we have treated 21 1p/19q-codeleted gliomas by neoadjuvant approach, and, of them, second-look removal after chemotherapeutic response was performed in 8 cases. There has been no recurrence in those tumors, and our results suggest efficacy of neoadjuvant approach for chemosensitive gliomas.
|
